Immediate Steps for Hypersensitivity Reactions
Lurbinectedin (trade name Zepzelca) hypersensitivity reactions, which occur in about 4-6% of patients, are managed by stopping the infusion right away. Mild reactions (grade 1-2) allow restarting at a slower rate after symptoms resolve—typically 25% reduction for the first restart, then 50% for subsequent ones. Severe reactions (grade 3-4) require permanent discontinuation.[1][2]
Premedication to Prevent Reactions
Patients get premedication before each dose: dexamethasone 10 mg IV (or equivalent) 30 minutes prior, plus an H1 antagonist like diphenhydramine 25-50 mg IV and an H2 antagonist like ranitidine 150 mg IV. This cuts reaction risk significantly.[1][3]
Rate Adjustments and Rechallenge Protocol
- First reaction: Reduce infusion rate by 25% (e.g., from 60 to 45 minutes).
- Second reaction: Further reduce by 50% from original (e.g., to 90 minutes).
- Monitor closely during rechallenge; anaphylaxis or grade 4 reactions end treatment permanently.
Infusions start at 60 minutes, extendable up to 180 minutes total.[1][2]
When to Stop Treatment Permanently
Discontinue lurbinectedin for any grade 3/4 hypersensitivity, confirmed anaphylaxis, or reactions not controlled by slowing the infusion. No rechallenge allowed in these cases.[1]
Patient Monitoring and Risks
Reactions often hit during or shortly after infusion, with symptoms like rash, dyspnea, or hypotension. Patients with prior hypersensitivity to other drugs need extra vigilance. Report severe cases to FDA MedWatch.[1][4]
[1]: Zepzelca (lurbinectedin) Prescribing Information, Jazz Pharmaceuticals, https://www.zepzelca.com/pdf/Zepzelca-PI.pdf
[2]: NCCN Guidelines for Small Cell Lung Cancer (Version 3.2023), https://www.nccn.org/guidelines
[3]: ESMO Management of Infusion Reactions Guidelines, https://www.esmo.org/guidelines
[4]: FDA Adverse Event Reporting System (FAERS) data on lurbinectedin, https://www.fda.gov/drugs